Today's PR is really important in terms of Accelerated Approval (AA). I hope AVXL applies for it ASAP. The solid data and the fact that there is no other available treatments should bode very well to get FDA support for AA. I followed the AA process with Sarepta closely and it appears the A-273 biomarker data are much stronger. A lot of Retts patients and their families all of a sudden have significant hope.